Search results for "Neoplasms"

showing 10 items of 7988 documents

TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma

2005

To prospectively evaluate the prognostic significance of TP53, H-, K-, and N-Ras mutations, DNA-ploidy and S-phase fraction (SPF) in patients affected by locally advanced laryngeal squamous cell carcinoma (LSCC). Eight-one patients (median follow-up was 71 months) who underwent resective surgery for primary operable locally advanced LSCC were analyzed. Tumor DNA was screened for mutational analysis by PCR/SSCP and sequencing. DNA-ploidy and SPF were performed by flow cytometric analyses. Thirty-six patients (44%) had, at least, a mutation in the TP53 gene. Of them, 22% (8/36) had double mutations and 3% (1/36) had triple mutations. In total, 46 TP53 mutations were observed. The majority (41…

squamous cell carcinomasingle strand conformation polymorphismPrognosipolymerase chain reactionDNA Mutational AnalysisEMTREE drug terms: protein p53 EMTREE medical terms: advanced cancerS PhaseDNA Mutational AnalysiHumansprotein p53 advanced cancer; article; cell cycle S phase; DNA content; exon; flow cytometry; follow up; gene; gene mutation; genetic analysis; histopathology; human; human tissue; larynx carcinoma; multivariate analysis; ploidy; polymerase chain reaction; priority journal; prospective study; single strand conformation polymorphism; squamous cell carcinoma; tp53 gene Carcinoma Squamous Cell; DNA Mutational Analysis; DNA Neoplasm; Genes ras; Humans; Laryngeal Neoplasms; Mutation; Ploidies; Polymorphism Single-Stranded Conformational; Prognosis; S Phase; Survival Rate; Tumor Suppressor Protein p53 [EMTREE drug terms]follow uplarynx carcinomatp53 gene MeSH: Carcinoma Squamous Cellexongene mutationhumanmultivariate analysigeneLaryngeal NeoplasmsPolymorphism Single-Stranded ConformationalLaryngeal NeoplasmPloidiesflow cytometryarticleploidyDNA NeoplasmPrognosisGenes rahuman tissueSurvival RateGenes rascell cycle S phasepriority journalDNA contentgenetic analysiMutationCarcinoma Squamous CellhistopathologyTumor Suppressor Protein p53Ploidieprospective study
researchProduct

Gastrointestinal Stromal Tumors (GISTs)

2021

Gastrointestinal stromal tumors (GISTs) are a group of tumors that, over the past 15 years, has emerged from a poorly understood neoplasm to a well-defined tumor entity. GISTs are highly resistant to conventional chemotherapy and, in the past, were typically managed surgically.

stomatognathic diseasesPathologymedicine.medical_specialtyStromal cellbusiness.industrymedicineConventional chemotherapyNeoplasmGastrointestinal stromal tumors (GISTs)businessmedicine.diseaseneoplasmsdigestive system diseases
researchProduct

The matrix metalloproteinase and insulin-like growth factor system in oral cancer – a prospective clinical study

2017

Eik Schiegnitz,1 Peer W Kämmerer,2 Holger Schön,1 Christoph Gülle,1 Manfred Berres,3,4 Keyvan Sagheb,1 Bilal Al-Nawas5 1Department of Oral and Maxillofacial Surgery, Plastic Surgery, University Medical Center, Johannes Gutenberg University of Mainz, Mainz, 2Department of Oral and Maxillofacial Surgery, Plastic Surgery, University Medical Centre Rostock, Rostock, 3Department of Mathematics and Technology, University of Applied Sciences Koblenz, Remagen, 4Institute of Medical Biometry, Epidemiology and Informatics, Johannes Gutenberg University of Mainz, Mainz, 5Department of Oral and Maxillofacial Surgery, Plastic Surgery, University Medical Centre, Martin-Luther University Ha…

stomatognathic diseasesserum biomarkerOSCCoral premalignant lesionprognosisoral cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282OncoTargets and Therapy
researchProduct

Dexamethasone premedication suppresses vaccine-induced immune responses against cancer

2020

ABSTRACT Glucocorticosteroids (GCS) have an established role in oncology and are administered to cancer patients in routine clinical care and in drug development trials as co-medication. Given their strong immune-suppressive activity, GCS may interfere with immune-oncology drugs. We are developing a therapeutic cancer vaccine, which is based on a liposomal formulation of tumor-antigen encoding RNA (RNA-LPX) and induces a strong T-cell response both in mice as well as in humans. In this study, we investigated in vivo in mice and in human PBMCs the effect of the commonly used long-acting GCS Dexamethasone (Dexa) on the efficacy of this vaccine format, with a particular focus on antigen-specif…

t-cell primingPremedicationmedicine.medical_treatmentImmunologyPriming (immunology)dexamethasoneglucocorticosteroidsProinflammatory cytokineMice03 medical and health sciences0302 clinical medicineImmune systemAntigenCancer immunotherapyNeoplasmsAnimalsHumansImmunology and AllergyMedicineRC254-282Original ResearchMice Inbred BALB Ccancer immunotherapybusiness.industryrna vaccineImmunityNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC581-607Mice Inbred C57BLCytokineOncology030220 oncology & carcinogenesisImmunologyt-cell vaccineFemaleCancer vaccineImmunologic diseases. AllergybusinessT-cell vaccineResearch Article030215 immunologyOncoImmunology
researchProduct

On the Choice of the Extracellular Vesicles for Therapeutic Purposes

2019

Extracellular vesicles (EVs) are lipid membrane vesicles released by all human cells and are widely recognized to be involved in many cellular processes, both in physiological and pathological conditions. They are mediators of cell-cell communication, at both paracrine and systemic levels, and therefore they are active players in cell differentiation, tissue homeostasis, and organ remodeling. Due to their ability to serve as a cargo for proteins, lipids, and nucleic acids, which often reflects the cellular source, they should be considered the future of the natural nanodelivery of bio-compounds. To date, natural nanovesicles, such as exosomes, have been shown to represent a source of diseas…

theranosticsregenerative medicineReviewexosomesBiologyRegenerative medicineExtracellular vesiclesCatalysisTheranostic NanomedicineCatalysiInorganic Chemistrylcsh:Chemistry03 medical and health sciencesParacrine signallingExtracellular Vesicles0302 clinical medicineDrug Delivery SystemsNeoplasmsAnimalsHumansPhysical and Theoretical ChemistryLipid bilayerMolecular Biologylcsh:QH301-705.5Tissue homeostasisSpectroscopy030304 developmental biology0303 health sciencesDrug CarriersVesicleOrganic ChemistrybiomarkersComputer Science Applications1707 Computer Vision and Pattern RecognitionBiological TransportGeneral MedicineBiomarkerMicrovesiclesnanodelivery3. Good healthComputer Science ApplicationsCell biologyExosomeTheranosticlcsh:Biology (General)lcsh:QD1-999030220 oncology & carcinogenesisSignal transductionextracellular vesicles (EVs)Signal TransductionInternational Journal of Molecular Sciences
researchProduct

MTOR inhibitor-based combination therapies for pancreatic cancer

2018

Background: Although the mechanistic target of rapamycin (MTOR) kinase, included in the mTORC1 and mTORC2 signalling hubs, has been demonstrated to be active in a significant fraction of patients with pancreatic ductal adenocarcinoma (PDAC), the value of the kinase as a therapeutic target needs further clarification. Methods: We used Mtor floxed mice to analyse the function of the kinase in context of the pancreas at the genetic level. Using a dual-recombinase system, which is based on the flippase-FRT (Flp-FRT) and Cre-loxP recombination technologies, we generated a novel cellular model, allowing the genetic analysis of MTOR functions in tumour maintenance. Cross-species validation and pha…

therapeutic resistance0301 basic medicineCancer ResearchCell SurvivalMAP Kinase Signaling Systempancreatic cancerAntineoplastic AgentsContext (language use)Mechanistic Target of Rapamycin Complex 2mTORC1Mechanistic Target of Rapamycin Complex 1BiologymTORC2BortezomibMice03 medical and health sciencesCell Line TumorPancreatic cancermedicineAnimalsHumansExtracellular Signal-Regulated MAP KinasesMechanistic target of rapamycinPI3K/AKT/mTOR pathwayBenzoxazolesKinaseMTORTOR Serine-Threonine Kinasesmedicine.diseaseddc:3. Good healthPancreatic NeoplasmsPyrimidines030104 developmental biologyOncologybiology.proteinCancer researchCamptothecinTOR Serine-Threonine KinasesPhosphatidylinositol 3-KinaseTranslational TherapeuticsProto-Oncogene Proteins c-aktBiologieCarcinoma Pancreatic Ductal
researchProduct

Response to the Letter to the editor regarding “Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carc…

2021

therapyCancer ResearchCarcinoma HepatocellularLetter to the editorbusiness.industryLiver Neoplasmshepatocellular carcinomamedicine.diseaseNeoplasm ProteinsGene Expression Regulation NeoplasticOncologyHepatocellular carcinomaCancer researchHumansMedicineStress ProteinsbusinessCancer Letters
researchProduct

Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy

2015

Recently, many studies explored the role of inflammation parameters in the prognosis of urinary cancers, but the results were not consistent. The modified Glasgow Prognostic Score (mGPS), a systemic inflammation marker, is a prognostic marker in various types of cancers. The aim of the present study was to investigate the usefulness of the preoperative mGPS as predictor of recurrence-free (RFS), overall (OS), and cancer-specific (CSS) survivals in a large cohort of urothelial bladder cancer (UBC) patients.A total of 1037 patients with UBC were included in this study with a median follow-up of 22 months (range 3-60 months). An mGPS = 0 was observed in 646 patients (62.3%), mGPS = 1 in 297 pa…

to-lymphocyte ratioAdultMaleRiskmedicine.medical_specialtyPrognosimedicine.medical_treatmentCystectomyGastroenterologySettore MED/24 - UrologiaCystectomyMedicine (all); c-reactive protein; advanced urothelial carcinoma; to-lymphocyte ratioc-reactive proteinRetrospective StudieInternal medicine80 and overHumansMedicineStage (cooking)advanced urothelial carcinomaRetrospective StudiesAgedAged 80 and overModified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience.Univariate analysisBladder cancerbusiness.industryProportional hazards modelMedicine (all)Hazard ratioBladder cancer Radical cystectomyRetrospective cohort studyGeneral MedicineMiddle AgedPrognosismedicine.diseaseSurgeryNeoplasm RecurrenceLocalUrinary Bladder NeoplasmsUrinary Bladder NeoplasmCohortFemaleNeoplasm Recurrence LocalAdult; Aged; Aged 80 and over; Female; Humans; Male; Middle Aged; Neoplasm Recurrence Local; Prognosis; Retrospective Studies; Risk; Urinary Bladder Neoplasms; Cystectomy; Medicine (all)businessHumanMedicine
researchProduct

Evaluation of Surgical Outcomes of Abdominal Radical Hysterectomy and Total Laparoscopic Radical Hysterectomy for Cervical Cancer: A Retrospective An…

2022

Although a surgical approach is one of the key treatments for stages IA1-IIA2, results of the Laparoscopic Approach to Cervical Cancer (LACC) published in 2018 radically changed the field, since minimally invasive surgery was associated with a four-fold higher rate of recurrence and a six-fold higher rate of all-cause death compared to an open approach. We aimed to evaluate surgical outcomes of abdominal radical hysterectomy (ARH) and total laparoscopic radical hysterectomy (TLRH) for cervical cancer, including data collected before the LACC trial. In our retrospective analysis, operative time was significantly longer in TLRH compared to ARH (p < 0.0001), although this disadvantage could…

total laparoscopic radical hysterectomycervical cancerHealth Toxicology and Mutagenesiscervical cancer; abdominal radical hysterectomy; total laparoscopic radical hysterectomy; minimally invasive surgery; surgical outcomesPublic Health Environmental and Occupational HealthUterine Cervical NeoplasmsHysterectomysurgical outcomesSettore MED/40 - Ginecologia E OstetriciaTreatment Outcomeabdominal radical hysterectomyHumansLaparoscopyFemaleabdominal radical hysterectomy; cervical cancer; minimally invasive surgery; surgical outcomes; total laparoscopic radical hysterectomy; Female; Humans; Retrospective Studies; Neoplasm Staging; Hysterectomy; Treatment Outcome; Uterine Cervical Neoplasms; Laparoscopyminimally invasive surgeryNeoplasm StagingRetrospective StudiesInternational Journal of Environmental Research and Public Health; Volume 19; Issue 20; Pages: 13176
researchProduct

Extracellular Vesicle microRNAs Contribute to the Osteogenic Inhibition of Mesenchymal Stem Cells in Multiple Myeloma

2020

Osteolytic bone disease is the major complication associated with the progression of multiple myeloma (MM). Recently, extracellular vesicles (EVs) have emerged as mediators of MM-associated bone disease by inhibiting the osteogenic differentiation of human mesenchymal stem cells (hMSCs). Here, we investigated a correlation between the EV-mediated osteogenic inhibition and MM vesicle content, focusing on miRNAs. By the use of a MicroRNA Card, we identified a pool of miRNAs, highly expressed in EVs, from MM cell line (MM1.S EVs), expression of which was confirmed in EVs from bone marrow (BM) plasma of patients affected by smoldering myeloma (SMM) and MM. Notably,we found that miR-129-5p, whic…

transcription factor sp1.Cancer ResearchBone diseaseosteogenic differentiationexosomeslcsh:RC254-282transcription factor sp1ArticleSettore MED/15 - Malattie Del SangueSettore BIO/13 - Biologia Applicatamedicinemultiple myeloma (MM)ChemistrySettore BIO/16 - Anatomia UmanaMesenchymal stem cellALPLOsteoblastMicroRNAExtracellular vesiclemedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSettore CHIM/08 - Chimica FarmaceuticaCell biologymicroRNAsExosomemedicine.anatomical_structureOncologyCell cultureAlkaline phosphatasebone diseaseBone marrowextracellular vesicles (EVs)Cancers
researchProduct